NCT00866762Unknown2 期
A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.
Copenhagen University Hospital at Herlev16 个研究点 分布在 4 个国家目标入组 60 人开始时间: 2009年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 16
- 主要终点
- To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.
研究概览
简要总结
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient > 18 years of age AND
- •A confirmed diagnosis of PV AND
- •Biochemical evidence of active disease as defined by:
- •a need for phlebotomy within last 3 months
- •a leukocyte count > 10 x 10^9/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET)
- •a platelet count > 450 x 10^9/L in the absence of infection or inflammation (normal CRP)(PV/ET) OR
- •Male or female patient > 18 years of age AND
- •A confirmed diagnosis of ET AND
- •Biochemical evidence of active disease as defined by *a platelet count > 450 x 10^9/L in the absence of infection or inflammation
- •Inclusion Criteria for both PV and ET:
- •Newly diagnosed or previously treated patient in chronic phase OR
- •Advanced phase PV or ET as defined by blasts of > 1 x 10^9/L in the peripheral blood and/or white cell count > 30 x 10^9/L OR
- •Resistant or refractory PV or ET as defined by haemoglobin < 10.5 gm/dl with a platelet count > 600 x 10^9/L on current therapy OR
- •Cycling platelet counts on therapy OR
- •Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon)
排除标准
- •A platelet count > 1500 x 10^9/L (a need for cytoreduction in platelet count)
- •Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug
- •Women who are breast feeding
- •Males and females not using contraceptives if sexually active.
- •EGOC Performance status Score > or = 3
- •Serum creatinine more than 2 x's teh ULN
- •Total serum bilirubin more than 1.5 x's the ULN
- •Serum AST/ALT more than 3 x's the ULN
- •Interferon alpha within 1 week of day 1
- •Hydroxycarbamide within 1 week of day 1
- •Anagrelide within 1 week of day 1
- •Valproic acid (as an anticonvulsant) within 28 days of day 1
- •Any other investigational drug within 28 days of day 1
- •Active HIV, HBV or HCV infection
- •Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance.
- •Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician.
- •Patient has a known allergy or hypersensitivity to study drug.
研究组 & 干预措施
1
Experimental
Treatment with study drug approximately 6 months and follow-up for 3 months
干预措施: HDAC inhibitor (MK-0683) (Drug)
结局指标
主要结局
To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.
时间窗: one year
次要结局
- To study changes in bone marrow morphology before and after treatment with study drug.(one year)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)Diabetes Mellitus, Type 2NCT00631488Merck Sharp & Dohme LLC146
已完成
2 期
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)Diabetic Neuropathy, PainfulNCT01564459Merck Sharp & Dohme LLC170
终止
2 期
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)Diabetes Mellitus Type 2NCT00543959Merck Sharp & Dohme LLC346
已完成
3 期
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)Benign Prostatic HyperplasiaNCT00127179Organon and Co600
已完成
1 期
A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)Solid TumorsNCT01071018Merck Sharp & Dohme LLC24